Trinity Biotech
TRIB
24 hedge funds and large institutions have $2.58M invested in Trinity Biotech in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 0 increasing their positions, 5 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
26% more funds holding
Funds holding: 19 → 24 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.31% less ownership
Funds ownership: 16.06% → 15.75% (-0.31%)
40% less capital inflows, than outflows
Capital inflows: $90.5K | Capital outflows: $151K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Becker Capital Management
Portland,
Oregon
|
+$43K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$15.5K |
| 3 |
Corient Private Wealth
Miami,
Florida
|
+$10.5K |
| 4 |
Two Sigma Securities
New York
|
+$9.09K |
| 5 |
Millennium Management
New York
|
+$7.37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aristides Capital
Louisville,
Kentucky
|
-$64.1K |
| 2 |
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
-$50.8K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$18.5K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$12.2K |
| 5 |
Renaissance Technologies
New York
|
-$4.44K |
TRIB Hedge Fund Activity: Q4 2023 in Review
24 of the 6,878 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q4 2023, worth a combined $2.58M — down 43% from $4.49M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TRIB positions and 2 closed out — a net gain of 5 holders — while 0 added to existing stakes and 5 trimmed.
The largest buyer was Becker Capital Management, opening a new position worth an estimated $43K. The largest seller was Aristides Capital, cutting an estimated $64.1K.
- 24 institutional investors held Trinity Biotech (TRIB) as of Q4 2023, up from 19 in Q3 2023.
- Funds reported $2.58M of Trinity Biotech stock for Q4 2023, down 43% quarter-over-quarter.
- 7 funds opened new Trinity Biotech positions in Q4 2023 and 2 closed out, a net change of +5 holders.
- The largest Trinity Biotech buyer in Q4 2023 was Becker Capital Management, an estimated $43K added.
- The largest Trinity Biotech seller in Q4 2023 was Aristides Capital, an estimated $64.1K sold.
Based on aggregated 13F filings for Q4 2023.